Strides Pharma Science Limited3 Months ended September 30, 2026 Results & Financial Update
Strides Pharma Science Limited: 3 Months ended September 30, 2026 consolidated results and company financials – revenue ₹1,429.73 Cr, PAT ₹134.12 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Strides Pharma Science price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Strides Pharma Science 3 Months ended September 30, 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Strides Pharma Science Limited posted consolidated revenue from operations of INR 1,429.73 crore for the quarter ended September 30, 2026, marking a 12.99% sequential expansion over the INR 1,265.41 crore reported in the preceding June 2026 quarter. s in its earnings presentation, total revenue grew approximately 17% year-on-year, propelled by robust momentum across international markets outside the US.
Profit after tax (PAT) for the quarter stood at INR 134.12 crore, representing an 18.96% decrease compared to INR 165.49 crore in Q1 FY27. This bottom-line contraction reflects higher material and logistics expenses alongside increased financing costs during the quarter, despite top-line growth.
Profit before tax (PBT) for Q2 FY27 came in at INR 150.44 crore, down 24.64% sequentially from INR 199.62 crore in the previous quarter. Basic and diluted earnings per share (EPS) for the quarter were recorded at INR 14.19, compared to INR 17.02 in the preceding period.
The company's performance benefited significantly from structural geographical diversification, with Ex-US markets generating INR 696.33 crore and surpassing the US business revenue of INR 685.50 crore for the first time on a quarterly basis. Ex-US markets grew by 31% year-on-year, driven by strong offtake in European partnered operations, the UK, Nordics, and brand-led growth in Africa.
Quarterly EBITDA crossed the INR 250 crore milestone for the first time, reaching INR 250.90 crore, up 8.4% year-on-year, supported by operating scale despite headwinds from geopolitical disruptions pushing up raw material and freight costs.
Reported net debt increased during the first half of FY27, reaching INR 1,647.90 crore as of September 30, 2026, up from INR 1,436.50 crore in March 2026. Management attributed this increase to an elongated cash-to-cash cycle and higher inventory holdings maintained to ensure industry-leading service levels amidst volatile macro conditions.
01 · Business model
What does Strides Pharma Science do?
Strides Pharma Science Limited is a global pharmaceutical company focused on the development, manufacture, and commercialization of finished dosage formulation products across multiple therapeutic categories.
The company operates primarily within a single reportable pharmaceutical segment, leveraging dedicated manufacturing and R&D facilities to serve regulated and emerging markets.
Strides maintains a diversified geographic footprint spanning the United States, various Ex-US international regions including Europe, the UK, Nordics, and South Africa, as well as institutional business channels.
02 · Historical context
What shaped the business before this quarter
Previously, the board approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab into Pivot Path, followed by the dilution of the group's controlling stake in Pivot Path on June 30, 2026, which yielded an exceptional net gain of INR 764.01 million.
Since earlier regulatory actions by the USFDA regarding impurity findings in Ranitidine and Losartan, the company has continued to carry provisions and incur legal and settlement expenses classified under exceptional items.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | 3 Months ended September 30, 2026 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹1,429.73 Cr | ₹1,265.41 Cr |
| Total income | ₹1,433.82 Cr | ₹1,270.30 Cr |
| Profit before tax | ₹150.44 Cr | ₹199.62 Cr |
| Profit after tax | ₹134.12 Cr | ₹165.49 Cr |
| EPS | ₹14.19 | ₹17.02 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Ex-US revenue grew 31% year-on-year to INR 6,963 million, outperforming the US business and driven by strong growth in European partnered products, the UK, Nordics, and African brand operations.
The US business recorded revenue of INR 6,855 million ($73 million), representing a 9% year-on-year increase, supported by 3 new product launches during the quarter and a portfolio where 38 products enjoy market-leading top-3 positions.
What drove margins
Gross margins moderated to 56.0% in Q2 FY27 compared to 60.9% in Q1 FY27 and 57.8% in Q2 FY26, impacted by higher input material and freight costs arising from geopolitical bottlenecks.
Total opex remained elevated as employee benefit expenses were recorded at INR 238.27 crore and other expenses stood at INR 311.12 crore, reflecting ongoing investments in commercial infrastructure and compliance.
05 · Demand, customers & order book
Where demand is coming from
As of October 2026, the company has filed 230 ANDAs in the US, with 212 approvals secured, encompassing 154 commercialized products and an active pipeline of over 40 value-accretive filings.
The controlled substances portfolio includes 5 commercialized products contributing ~6% of US revenue, alongside a pipeline of 10+ products including nasal sprays, patches, and films addressing a total addressable market of $4.5 billion.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The Chief Operating Decision Maker evaluates the group as a single reportable pharmaceutical segment comprising the development, manufacture, and commercialization of non-biological pharmaceutical formulations.
Geography and market mix
Ex-US markets accounted for 49% of Q2 FY27 revenue, matching the US market share of 48%, while tactical business (Access markets) contributed 3%.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company's US manufacturing facility at Chestnut Ridge possesses the required capacity and regulatory expertise to support the expansion of the controlled substances and specialized delivery platform strategy.
Projects, capex and execution
Capital expenditure for property, plant, equipment, and intangibles totaled INR 2,664.51 million for the half-year ended September 30, 2026.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Management continues to rebalance growth engines toward Ex-US territories while maintaining disciplined investments in complex generic platforms such as nasal sprays, topical patches, and films.
09 · Reported developments
What changed operationally
Ex-US quarterly revenue exceeded US revenue for the first time, validating the multi-geography diversification strategy.
Quarterly EBITDA crossed INR 2,500 million for the first time, reaching INR 2,509 million.
10 · Pressure points & risks
What is not going smoothly
Gross and EBITDA margins contracted year-on-year due to freight inflation, geopolitical supply chain friction, and higher raw material costs.
11 · Items worth noticing
The line items that can distort a quick read
The company recorded a net exceptional expense of INR 17.04 million during Q2 FY27, primarily reflecting product recall provisions, legal fees, and settlement expenses associated with legacy ranitidine and testosterone product matters.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash generated from operating activities for H1 FY27 was INR 1,065.72 million, impacted by an elongated cash-to-cash cycle (137 days) and higher inventory holdings of INR 1,873.47 crore as of September 30, 2026.
Capital allocation & funding
Gross debt rose to INR 1,847.10 crore as of September 30, 2026, comprising working capital loans of INR 1,205.40 crore and long-term loans of INR 641.70 crore. Reported net debt stood at INR 1,647.90 crore after deducting cash and cash equivalents of INR 199.20 crore.
13 · Management guidance & targets
What management is targeting from here
Management noted that the US revenue aspiration of ~$375m has shifted beyond FY28 due to quota constraints and normalization of drug shortages, while expecting the Net Debt to EBITDA ratio to stabilize by the end of the fiscal year.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Appointment
Mr. Biren Gabhawala was appointed as a Non-Executive Independent Director effective November 1, 2026, subject to shareholder approval, bringing over three decades of audit and governance experience.
15 · Previous-quarter changes
What changed since the previous quarter
Revenue expanded by 12.99% QoQ from INR 1,265.41 crore in Q1 FY27 to INR 1,429.73 crore in Q2 FY27.
16 · Key Q&A
The quarter, answered directly
What does Strides Pharma Science do?
Strides Pharma Science Limited is a global pharmaceutical company focused on the development, manufacture, and commercialization of finished dosage formulation products across multiple therapeutic categories.
What is the clearest takeaway from 3 Months ended September 30, 2026?
Strides Pharma Science Limited posted consolidated revenue from operations of INR 1,429.73 crore for the quarter ended September 30, 2026, marking a 12.99% sequential expansion over the INR 1,265.41 crore reported in the preceding June 2026 quarter. s in its earnings presentation, total revenue grew approximately 17% year-on-year, propelled by robust momentum across international markets outside the US.
What drove revenue or demand?
Ex-US revenue grew 31% year-on-year to INR 6,963 million, outperforming the US business and driven by strong growth in European partnered products, the UK, Nordics, and African brand operations.
What mattered most for margins or profitability?
Gross margins moderated to 56.0% in Q2 FY27 compared to 60.9% in Q1 FY27 and 57.8% in Q2 FY26, impacted by higher input material and freight costs arising from geopolitical bottlenecks.
What changed operationally beyond the headline numbers?
The company's US manufacturing facility at Chestnut Ridge possesses the required capacity and regulatory expertise to support the expansion of the controlled substances and specialized delivery platform strategy.
What is management guiding or targeting from here?
Management noted that the US revenue aspiration of ~$375m has shifted beyond FY28 due to quota constraints and normalization of drug shortages, while expecting the Net Debt to EBITDA ratio to stabilize by the end of the fiscal year.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Net Debt to EBITDA Stabilization: Monitor the stabilization of the Net Debt to EBITDA ratio and working capital normalization by the end of FY27.
- 02
Controlled Substance Ramp-up: Track regulatory quota allocations and commercial progress on the US controlled substance pipeline, including upcoming GDUFA goal dates for nasal sprays.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.